Evidence map›Paper›PMID 41719494›Full record

ArticleNeurology2026

Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.

Andria L Ford, Peter Kang, Slim Fellah, Serguei V Astafiev, April Ratliff, Mark Fiala, Yan Wang, Vivian Chen, Sydney Panagos, Henok Getahun and 8 more

Abstract read
In one paragraph

Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Headache Attributed to Genetic Vasculopathies.Current pain and headache reports · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Andria L FordDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-0605-8943
Peter KangDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-9823-4440
Slim FellahDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-6179-6389
Serguei V AstafievDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-3736-7095
April RatliffCenter for Biostatistics and Data Science, Washington University School of Medicine, St. Louis, MO.
Mark FialaDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0208-5023
Yan WangDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-3750-0311
Vivian ChenDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.
Sydney PanagosDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.
Henok GetahunJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO.
Yasheng ChenDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-1133-452X
Rajendra S ApteJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-2281-2336
M Kathryn LiszewskiDepartment of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO.
Jason HassenstabDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-7802-3371
Jonathan J MinerDepartment of Medicine, Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; and.
John P AtkinsonDepartment of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO.
Jin-Moo LeeDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-3979-0906
Hongyu AnDepartment of Neurology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-6459-2269

Funding

MR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell DiseaseR01HL129241 · NHLBI · WASHINGTON UNIVERSITY · PI Hongyu An, Robert A Campbell · 2015 to 2026
$6.6M
MR measured regional hypoxia as an early biomarker in cerebral small vessel diseaseRF1NS116565 · NINDS · WASHINGTON UNIVERSITY · PI AN, HONGYU, FORD, ANDRIA LEE · 2020 to 2020
$3.4M
NHLBI NIH HHS R01 HL129241NINDS NIH HHS RF1 NS116565
6 · The paper itself

Abstract

BACKGROUND AND

objectivesA monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression.

methodsWe performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression.

resultsTwenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83, DISCUSSION: Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.

Indexed as

Cognitive DysfunctionLeukoencephalopathiesAdultAgedBiomarkersCerebrovascular CirculationDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeuroimagingProspective StudiesWhite MatterBiomarkers

Identifiers

PMID41719494
PMCPMC13616444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.